← Back to homeJohnson & Johnson Prostate Cancer Pill Shrinks Tumors in Early Trial
In an early study, most men with advanced, treatment-resistant prostate cancer on the 50-milligram dose of JNJ-6143 saw PSA levels fall by half.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources Brief
An experimental once-daily pill from Johnson & Johnson shrank or eliminated tumors in some men with advanced…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
2 sources behind this story.
By NewsPlain Editorial Team · Published
About this story
We haven’t published a correction to this story.
How NewsPlain works ← Back to home